Passage Bio's Upcoming Presentation at a Healthcare Conference
Passage Bio, Inc. (NASDAQ: PASG), a pioneering company focused on genetic medicines, is set to participate in a notable healthcare event. The president and CEO, Will Chou, M.D., will engage in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. This event is scheduled for November, and it promises to showcase the latest advancements in healthcare innovations.
What to Expect from the Conference
The conference is not just a gathering; it's an opportunity for Passage Bio to highlight its groundbreaking work in genetically targeted therapies aimed at treating neurodegenerative diseases. As a clinical stage company, their mission revolves around enhancing patients’ lives through innovative solutions. Attendees can look forward to insights into their lead product candidate, PBFT02, which holds promise for conditions like frontotemporal dementia.
Live Webcast for Interested Audience
A live webcast of the discussion will be accessible to the public, fostering wider engagement with the community. This initiative reflects Passage Bio's commitment to transparency and education regarding their work and advancements in the field of genetic medicine. For 90 days post-event, the recorded session will be available, allowing those who cannot attend live to catch up on the latest information.
Understanding Passage Bio's Mission
At the heart of Passage Bio is the dedication to combating neurodegenerative disorders by addressing their core biological causes. With a focus on groundbreaking one-time therapies, the company is determined to alter the course of diseases that impact many lives. Their innovative approach includes elevating progranulin levels, an essential factor in maintaining lysosomal function and halting disease progression.
The Significance of PBFT02
The company’s flagship candidate, PBFT02, represents a significant leap forward in treating challenging conditions such as frontotemporal dementia. By working to restore lysosomal functionality, this candidate aims to slow disease progression and improve outcomes for patients and their families. This therapeutic development aligns with the broader goal of Passage Bio to not only treat but transform the standard of care in neurodegenerative diseases.
Commitment to Patients and Families
Passage Bio stands firm in its commitment to protect patients affected by neurodegenerative conditions. Their efforts extend beyond just the development of therapies; they aspire to create a supportive environment for families navigating these challenging situations. With ongoing research and a dedication to advancement, the company aims to be a beacon of hope for those in need.
Investor and Media Relations
For interested investors and media personnel, Passage Bio has provided key contact information. Stuart Henderson represents the investor side, ensuring effective communication and transparency. For media inquiries, Mike Beyer from Sam Brown Inc. Healthcare Communications is available for further information.
Frequently Asked Questions
What is Passage Bio focused on?
Passage Bio is a clinical stage genetic medicines company targeting neurodegenerative diseases with innovative therapies.
Who is participating in the upcoming conference?
Will Chou, M.D., the president and CEO of Passage Bio, will participate in the Guggenheim Securities conference.
What is the lead product candidate of Passage Bio?
The lead product candidate is PBFT02, aimed at treating frontotemporal dementia by restoring lysosomal function.
How can one access the conference presentation?
The conference will be live-streamed, and a replay will be available for 90 days on the company’s website.
Who can be contacted for more information?
Investors can contact Stuart Henderson, while media inquiries can go to Mike Beyer at Sam Brown Inc.
